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OBJECTIVES This study was designed to determine the effect of two weeks’ treatment with L-arginine on
the ratio of plasma L-arginine to asymmetric dimethylarginine (ADMA), oxidative stress,
endothelium-dependent vasodilatation to acetylcholine, exercise performance and heart rate
variability in men with stable angina.
BACKGROUND The ratio of plasma L-arginine:ADMA has been proposed as a determinant of endothelium-
dependent dilation; dietary supplementation with L-arginine has been shown to improve
endothelium-dependent vasodilation and symptoms in some conditions.
METHODS Men (n 5 40) with stable angina, at least one epicardial coronary artery with a stenosis .50%
and a positive exercise test were randomized to receive L-arginine (15 g daily) or placebo for
two weeks according to a double-blind parallel-group design. Plasma L-arginine, ADMA,
8-epi-prostaglandin F2a (a marker of oxidative stress) and forearm vasodilator responses to
brachial artery infusion of nitroprusside and acetylcholine (6L-arginine) were measured. A
standard Bruce protocol exercise test was performed before and at the end of the treatment
period.
RESULTS Plasma L-arginine increased after oral L-arginine, whereas ADMA remained unchanged,
leading to an increase in the L-arginine/ADMA ratio of 62 6 11% (mean 6 SE, p , 0.01).
Despite a significant enhancement in acetylcholine response by intra-arterial L-arginine at
baseline, this response remained unchanged after oral L-arginine. Measures of oxidative stress
and exercise performance after L-arginine/placebo were similar in placebo and active groups.
CONCLUSIONS In men with stable angina, an increase in plasma L-arginine/ADMA ratio after two weeks’
oral supplementation with L-arginine is not associated with an improvement in endothelium-
dependent vasodilatation, oxidative stress or exercise performance. (J Am Coll Cardiol 2001;
38:499–505) © 2001 by the American College of Cardiology
L-arginine, the physiological substrate for nitric oxide (NO)
synthesis (1), improves endothelium-dependent vasodila-
tion in hypercholesterolemic humans (2–4) and, in animal
models, has anti-atherogenic actions reducing oxidative
stress (5), platelet aggregation (6,7), monocyte adhesion
(8,9) and the formation of intimal lesions (10,11). De-
creased platelet aggregation has also been observed in
humans (12). Such actions suggest a potential therapeutic
role for L-arginine. Short-term administration of L-arginine
produces vasodilation in patients with critical limb ischemia
(13). When given orally, or as repeated parenteral infusions,
L-arginine improves symptoms of claudication in patients
with peripheral vascular disease (14,15). In patients with
nonobstructive coronary artery disease (CAD), endothelium-
dependent vasodilator responses are improved, with a reduc-
tion in symptoms and an improved exercise tolerance (16).
Beneficial effects of L-arginine are thought to result from
increased NO production (17). The mechanism by which
this occurs is controversial, however, because intracellular
concentrations of L-arginine greatly exceed the Michaelis-
Menton rate constant of endothelial NO synthase (NOS)
(18). One possibility is that endothelial dysfunction is
associated with an increase in asymmetric dimethylarginine
(ADMA) (19) and possibly other endogenous inhibitors of
NOS (20). Such inhibitors may compete with L-arginine as
a substrate for NOS, increase oxidative stress (possibly via
uncoupling of electron transport between NOS and
L-arginine) and decrease the production/availability of
endothelium-derived NO (20). As a result, endothelium-
dependent vasodilation may be dependent on the plasma
L-arginine/ADMA ratio (21).
The purpose of the present study was to determine
whether endothelium-dependent vasodilation in men with
stable angina that was caused by obstructive CAD correlates
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with the L-arginine/ADMA ratio and whether oral supple-
mentation with L-arginine decreases oxidative stress and
improves endothelium-dependent vasodilation. Further end
points were to determine whether oral L-arginine supple-
mentation improves myocardial ischemia or heart rate
variability, a risk factor that may be influenced by
L-arginine (22).
METHODS
Subjects. Men with stable angina (n 5 40) fulfilling the
study’s inclusion and exclusion criteria were consecutively
recruited after coronary angiography for investigation of
angina. The study was approved by the St. Thomas’
Hospital Research Ethics Committee, and all subjects gave
written informed consent. Inclusion criteria comprised sta-
ble angina, at least one epicardial coronary artery with a
stenosis .50% and a positive exercise test, defined as either
1 mm ST depression in two or more leads and/or anginal
symptoms during the test. Exclusion criteria comprised an
acute coronary syndrome within the previous three months,
triple-vessel or left main stem disease requiring urgent
revascularization, prior coronary artery bypass grafting, left
ventricular failure with an ejection fraction (estimated from
ventriculography) ,30%, arrhythmias requiring treatment,
diabetes mellitus, clinically significant renal, liver or sys-
temic disease or anticoagulation or anti-oxidant treatment.
Lipid-lowering medication was stopped for four weeks
before the first visit and for the duration of the study.
Baseline characteristics obtained after this period are shown
in Table 1.
Study design. Subjects were randomized to receive either
5 g L-arginine (Martindale Pharmaceuticals, Romford,
United Kingdom) or lactose placebo three times a day for
two weeks according to a parallel-group double-blind
placebo-controlled design. Investigations before and at the
end of the supplementation period were performed over two
days. Oral nitrates were withheld 24 h before each visit until
completion of the investigations on the second day. On the
first day of each visit, fasting blood samples were collected
for L-arginine, ADMA, symmetric dimethylarginine
(SMDA), 8-epi PGF2a, total and high density lipoprotein
cholesterol, triglycerides, and renal and liver function tests.
Forearm blood flow responses were determined, followed by
attachment of a 24-h Holter recorder. Subjects returned on
the second day for removal of the Holter recorder and to
perform an exercise treadmill test.
Plasma L-arginine, ADMA, SDMA and 8-epi-PGF2a.
Plasma concentrations of L-arginine, ADMA and SDMA
were measured by high-performance liquid chromatography
and precolumn derivatization with o-phthaldialdehyde as
previously described (21). Plasma concentrations of 8-epi-
PGF2a, a nonenzymic oxidation product of arachidonic
acid, were used as a marker of oxidative stress (23). The
compound 8-epi-PGF2a was determined by negative-ion
chemical ionization mass spectrometry using tetradeuter-
ated 8-epi-PGF2a as internal standard (24).
Forearm blood flow studies. Forearm blood flow measure-
ments were performed in a quiet clinical laboratory (tem-
perature 24°C). Blood flow was measured in both forearms
using venous occlusion plethysmography with electrically
calibrated strain gauges (25,26). Wrist occlusion pressure
was 180 mm Hg, and collecting cuff pressure 40 mm Hg.
An unmounted 27-gauge steel needle (Cooper’s Needle-
works, Birmingham, United Kingdom) was sealed by dental
wax to an epidural catheter and inserted into the left
brachial artery under sterile conditions using ,1 ml of 1%
lignocaine hydrochloride to provide local anesthesia. After
cannulation of the brachial artery, saline was infused at
1 ml/min for 20 min using a constant-rate infusion pump.
A cumulative rising dose of nitroprusside (David Bull
Laboratories, Victoria, Australia, 3, 10 and 30 nmol/min,
each dose for 5 min) was infused and, after a 15 min
washout period was followed by acetylcholine (CIBA Vision
Opthalmics, Southampton, United Kingdom, 40, 80 and
160 nmol/min, each dose for 5 min). Finally, after a further
20 min washout period, L-arginine (Torbay Pharmacy,
Torbay Hospital, United Kingdom, 50 mmol/min) was
infused alone and then co-infused during a second identical
Abbreviations and Acronyms
ADMA 5 asymmetric dimethylarginine
AUC 5 area under forearm blood flow dose
response curve
CAD 5 coronary artery disease
8-epi-PGF2a 5 8-epi-prostaglandin-F2a
LDL 5 low-density lipoprotein
NO 5 nitric oxide
NOS 5 nitric oxide synthase
SDMA 5 symmetric dimethylarginine
Table 1. Subject Characteristics
L-Arginine
(n 5 21)
Placebo
(n 5 19)
Age (yrs) 60 6 2 63 6 2
Smokers 6 (29%) 1 (5%)*
BMI (kg/m2) 27 6 1 26 6 1
Total cholesterol (mmol/l) 5.7 6 0.2 6.5 6 0.2*
LDL cholesterol (mmol/l) 3.7 6 0.2 4.2 6 0.2
HDL cholesterol (mmol/l) 1.3 6 0.1 1.2 6 0.0
Triglycerides (mmol/l) 1.6 6 0.2 2.3 6 0.3*
Blood pressure (mm Hg) 143/78 6 4/2 145/78 6 4/2
Anatomy—1-vessel 5 (24%) 4 (21%)
Anatomy—2-vessel 3 (14%) 5 (26%)
Anatomy—3-vessel 13 (62%) 10 (53%)
Myocardial infarction 11 (52%) 10 (53%)
History of hypertension 12 (57%) 9 (47%)
Medication—ACE inhibitors 2 (10%) 3 (16%)
Medication—beta-blockers 18 (86%) 11 (58%)*
Medication—Ca11 antagonists 6 (29%) 14 (74%)*
Medication—nitrates 2 (10%) 8 (42%)*
Medication—nicorandil 1 (5%) 1 (5%)
* p , 0.05 compared with L-arginine group. Values are means 6 SE or %.
ACE 5 angiotensin-converting enzyme; BMI 5 body mass index; HDL 5
high-density lipoprotein; LDL 5 low-density lipoprotein.
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cumulative rising dose infusion of acetylcholine. Forearm
blood flow was recorded during the last 3 min of each
infusion period using 10-s venous occlusions every 20 s.
Blood flow was calculated from the mean of the last five
venous inflations and expressed in units of ml/min per 100
ml of forearm volume (25). Blood pressure was measured by
mercury sphygmomanometry at the end of the study. Area
under dose response curve (AUC, arbitrary units) was
calculated using values of absolute blood flow (27) for blood
flow responses to nitroprusside, acetylcholine and acetylcho-
line in the presence of L-arginine.
Exercise treadmill test. Symptom-limited standard Bruce
protocol exercise tests were performed by the same investi-
gators, blind to conditions. In one patient the test was
terminated because of development of ST depression
.4 mm. In addition to total exercise time, other parameters
studied included time to 1 mm ST depression (for a
minimum of 10 consecutive beats), time to onset of symp-
toms and rate pressure product.
24-h electrocardiographic recording. Heart rate variabil-
ity was determined from 24-h ambulatory recording of the
electrocardiograph using two-channel Oxford Tracker 2
recorders (Reynolds Medical Ltd., Hertford, United King-
dom). Tape recordings free of ectopic beats and artifact were
analyzed for heart rate variability in the time domain using
Reynolds Professional and Century 3000 analysis software
(Reynolds Medical Ltd., Hertford, United Kingdom) as
recommended by the 1996 European Task Force Guide-
lines (28).
Statistical power and analysis. Power calculations were
based upon the previously assessed reproducibility of the
blood flow responses to acetylcholine measured by forearm
plethysmography (27). A sample size of 40 was estimated to
allow a 20% difference in the AUC to acetylcholine to be
determined with a power of .90%. Baseline characteristics
were compared using chi-squared or Student t test. Corre-
lations were sought using least-squares regression analysis
and analysis of covariance where appropriate. Outcome
measures were compared between groups using two-way
analysis of variance. Forearm blood flow responses were
assumed to be log normally distributed (27), and statistical
analysis was performed on log-transformed data, with p ,
0.05 (two-sided) being taken as significant.
RESULTS
One subject in the L-arginine group (n 5 21) developed
unstable angina and was admitted for percutaneous angio-
plasty; a second subject in the placebo group (n 5 19) was
unable to complete the study, because of a viral illness.
Analysis was thus performed on 20 subjects who received
L-arginine and 18 who received placebo. Blood pressure
and lipid profiles remained similar before and after supple-
mentation in both groups (Table 2).
Plasma L-arginine, ADMA, SDMA and 8-epi PGF2a.
Baseline values of L-arginine were similar to those previ-
ously obtained in control subjects, but those of ADMA were
higher, with the ratio of L-arginine/ADMA ,50% of that
seen in historical controls and similar to values obtained in
hypercholesterolemic subjects (21). After supplementation
with L-arginine, plasma L-arginine increased from 80 6 2
mmol/l to 117 6 4 mmol/l (p , 0.001), whereas in the
placebo group, L-arginine remained unchanged. Plasma
ADMA, SDMA and 8-epi-PGF2a remained similar before
and after supplementation in both groups (Table 2). The
mean increase in L-arginine/ADMA ratio in the L-arginine
group was 62 6 11% (p , 0.01).
Forearm blood flow responses. Forearm blood flow re-
sponses to brachial artery infusion of nitroprusside and
acetylcholine are shown in Figure 1. Responses to acetyl-
choline were impaired by 20% relative to age-matched
historical controls. In the placebo group blood-flow re-
sponses to nitroprusside and acetylcholine did not change
significantly after supplementation (AUC for nitroprusside
at baseline: 21.5 6 1.4 vs. 22.6 6 1.4 arbitrary units after
placebo; AUC for acetylcholine at baseline: 24.8 6 3.4 vs.
25.8 6 2.6 after placebo). After L-arginine supplementation
Table 2. Plasma Concentrations of Arginine, Methylarginines, 8-epi-PGF2a, Lipid Profiles and
Blood Pressure Before (Visit 1) and at the End (Visit 2) of Treatment With Oral
Arginine/Placebo
L-Arginine Placebo
Visit 1 Visit 2 Visit 1 Visit 2
L-arginine (mmol/l) 80 6 2 117 6 4* 83 6 4 89 6 5
ADMA (mmol/l) 5.6 6 0.3 5.4 6 0.4 4.9 6 0.3 4.8 6 0.3
SDMA (mmol/l) 0.59 6 0.05 0.79 6 0.10 0.60 6 0.06 0.61 6 0.06
L-arg/ADMA 15.1 6 1.0 23.6 6 1.5* 17.6 6 1.1 20.1 6 1.6
8-epi-PGF2a (nmol/l) 0.30 6 0.05 0.22 6 0.03 0.25 6 0.04 0.24 6 0.04
LDL-chol (mmol/l) 3.7 6 0.2 3.9 6 0.2 4.2 6 0.2 4.5 6 0.2
HDL-chol (mmol/l) 1.3 6 0.1 1.3 6 0.1 1.2 6 0.1 1.2 6 0.1
Triglycerides (mmol/l) 1.6 6 0.2 1.5 6 0.1 2.3 6 0.3 2.5 6 0.4
Blood pressure (mm Hg) 143/78 6 4/2 140/79 6 4/2 145/75 6 4/2 141/76 6 4/2
* p , 0.01 compared with visit 1.
ADMA 5 asymmetric dimethylarginine; HDL-chol 5 high density lipoprotein cholesterol; L-arg/ADMA 5 ratio of
L-arginine to ADMA: LDL-chol 5 low density lipoprotein cholesterol.
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there was a small but significant decrease in the response to
nitroprusside (AUC 21.1 6 1.4 at baseline compared with
18.5 6 1.2 after supplementation, p , 0.01 for the change
relative to that in the placebo group). There was a nonsig-
nificant trend to a lower response to acetylcholine after
L-arginine (22.3 6 2.8 vs.19.7 6 2.9, p , 0.1 for the
change relative to that in the placebo group). The upper
95% confidence limit for an improvement in blood flow
response (AUC) to acetylcholine after oral L-arginine
(relative to placebo) was 3%. There was no correlation
between AUC for acetylcholine and the L-arginine/ADMA
ratio at baseline (r 5 0.28, p 5 0.10). The within-subject
coefficient of variation for the AUC response for acetylcho-
line calculated from the baseline and placebo visits was 28%.
Effects of intra-arterial L-arginine. At baseline, intra-
arterial L-arginine produced a similar increase in the AUC
response to acetylcholine in the L-arginine group (18.3 6
1.8% increase) and in the placebo group (19.5 6 8.5%
increase, each p , 0.01). After supplementation, the cor-
responding values were 26 6 9.8% and 33.3 6 12.4% in the
L-arginine and placebo groups, respectively (p 5 ns com-
pared with baseline). There was no correlation between the
percent increase in forearm blood flow response to acetyl-
choline in the presence of intrabrachial L-arginine with the
plasma L-arginine/ADMA ratio at baseline (r 5 20.06,
p 5 0.6). During short-term intra-arterial infusion of
L-arginine, plasma concentrations of L-arginine in the
infused arm were estimated (from the rate of drug infusion
and forearm blood flow) to be approximately 500 mmol/L,
more than fivefold higher than baseline values, producing an
increase in the L-arginine/ADMA ratio of approximately
500%.
Exercise tests. No significant differences were observed in
the incidences of ST depression and symptoms in either
group before or after supplementation (Table 3). Total
exercise time increased within both groups, from 452 6 30 s
to 497 6 31 s in the L-arginine group, and from 467 6 36 s
to 520 6 37 s in the placebo group (each p , 0.01).
However, there was no significant difference between
groups (p 5 0.7). Similarly, changes in rate pressure
product, time to 1 mm ST depression or time to onset of
symptoms in L-arginine and placebo groups were similar.
Figure 1. Forearm blood flow responses to a) acetylcholine (ACh) at baseline and after placebo; b) ACh at baseline and after L-arginine; c) nitroprusside
(NP) at baseline and after placebo; d) nitroprusside at baseline and after L-arginine. Responses to NP decreased significantly (p , 0.01) after L-arginine
compared with placebo by two-way analysis of variance. Those to ACh tended to decrease but the difference did not reach significance (p , 0.1).
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24-h Holter monitoring and heart rate variability. There
were no significant changes in indices of overall, short- and
long-term heart rate variability: standard deviation of R-R
intervals, standard deviation of mean R-R intervals calcu-
lated over 5-min intervals or root mean square of differences
between successive R-R intervals in either group (data not
shown).
DISCUSSION
Effects of short-term intra-arterial L-arginine on
endothelium-dependent vasodilation. L-arginine has re-
ceived much attention as a potential treatment for condi-
tions associated with endothelial dysfunction (17), its effects
being attributed to an increase in the plasma L-arginine/
ADMA ratio (29). Short-term intra-arterial administration,
producing an increase of approximately 500% in the L-
arginine/ADMA ratio, improved vascular responses to bra-
chial artery infusion of acetylcholine in the men with stable
angina in this study. This observation is consistent with
those of other investigations (2,3,30,31). However, the
blood-flow response to acetylcholine was not significantly
correlated with the plasma L-arginine/ADMA ratio. Fur-
thermore, the improvement in blood flow obtained by
short-term intra-arterial infusion of L-arginine did not
correlate significantly with the plasma L-arginine/ADMA
ratio. This suggests that the plasma L-arginine/ADMA
ratio is not a major determinant of endothelium-dependent
vasodilation in these patients.
Lack of effect of oral L-arginine on endothelial function.
Oral supplementation with L-arginine resulted in a 60%
increase in the L-arginine/ADMA ratio. However, we did
not observe any improvement in vascular function. Indeed,
there was a quantitatively small but statistically significant
decrease in response to the NO donor nitroprusside and a
tendency for a decreased response to acetylcholine. Thus,
although the variability of the response to acetylcholine was
greater than in previous studies (27), the upper 95% confi-
dence limit for the improvement in blood flow response
(AUC) to acetylcholine after oral L-arginine (relative to
placebo) was only 3%. We cannot exclude the possibility
that the failure to produce an improvement in the acetyl-
choline response was due to the relatively modest increase in
L-arginine/ADMA ratio (compared with that achieved
with intra-arterial L-arginine). However, these observa-
tions, taken together with the lack of correlation between
the acetylcholine response and the L-arginine/ADMA ra-
tio, argue against an important influence of the arginine/
ADMA ratio in determining endothelium-dependent vaso-
dilation in patients with symptomatic atherosclerotic CAD.
The dose of L-arginine used is close to the maximum
tolerated (32). Thus, even if the L-arginine/ADMA ratio is
an important determinant of the acetylcholine response, the
present findings suggest that oral L-arginine is unlikely to
elevate this enough to improve endothelial function in these
patients.
Lack of effect of L-arginine on oxidative stress.
L-arginine reduces the production of superoxide anion in
endothelial cells incubated with low-density lipoprotein
(LDL) (33) and reduces urinary 8-epi-PGF2a in
cholesterol-fed rabbits (5). Our study is the first, to our
knowledge, to assess the effects of oral L-arginine supple-
mentation on the plasma marker of oxidative stress 8-epi-
PGF2a. Although 8-epi-PGF2a cannot be regarded as a
universal marker of oxidant stress (for example, lipid per-
oxidation may not occur, despite increased oxidant stress,
because of protection by anti-oxidants), it is a more sensitive
marker of oxidative injury in endothelial cells than other
indices such as concentrations of thiobarbituric acid reactive
substances (34). Furthermore, we have previously demon-
strated changes in 8-epi-PGF2a to parallel those in
endothelium-dependent dilation (35). Lack of effect of oral
L-arginine on plasma 8-epi-PGF2a suggests that the results
observed in hypercholesterolemic rabbits cannot necessarily
be extrapolated to patients with CAD.
Lack of effect of L-arginine on exercise performance and
heart rate variability. Short-term administration of
L-arginine improves coronary microvascular function in
hypercholesterolemic subjects (3) and therefore might be
expected to improve myocardial ischemia in patients with
stable angina. In the present study, however, we observed no
greater improvement in exercise tolerance than in the
placebo group. These findings do not, therefore, support a
role for L-arginine as an anti-anginal agent. The possibility
that L-arginine modulates parasympathetic tone, which is a
major determinant of heart rate variability, was raised in an
earlier study (22), but the present study does not support
this conclusion in men with stable angina.
Comparison with other studies of L-arginine supplemen-
tation. The lack of effect of increasing the L-arginine/
ADMA ratio on endothelial function and on oxidative
Table 3. Exercise Tolerance and Ischemia Before (Visit 1) and at the End (Visit 2) of
Treatment With Oral Arginine/Placebo
L-Arginine Placebo
Visit 1 Visit 2 Visit 1 Visit 2
Total exercise time(s) 452 6 30 497 6 31* 467 6 36 520 6 37*
Rate pressure product (mm Hg/s) 215 6 12 218 6 13 223 6 12 216 6 11
Time to 1 mm ST depression(s) 352 6 42 339 6 36 325 6 63 306 6 55
Time to symptoms (s) 348 6 32 404 6 40 314 6 36 305 6 38
*p , 0.05 compared with visit 1.
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stress in the present study contradicts findings in animals
and in some but not all of the clinical studies. Oral
L-arginine increases flow-mediated dilation (FMD) of the
brachial artery in young hypercholesterolemic subjects with
no evidence of CAD (4) and has also been shown to
improve FMD in young men with CAD (36). In this study,
L-arginine 7 g three times a day led to a marked improve-
ment in flow-mediated brachial artery dilation within three
days. Although mean LDL cholesterol was similar to that in
the present study, the subjects were younger (41 6 2 years)
and were selected on the basis of poor endothelial function.
A dose of 3 g three times a day improved endothelial
function and symptoms in patients with nonobstructive
CAD (16). However, subjects with heart failure did not
benefit from a four-week course of L-arginine 20 g daily
(37). In a recent study in a group of 29 patients with similar
characteristics to those in the present study, L-arginine 9 g
per day for 28 days produced no effect on nitrogen oxides or
FMD of the brachial artery, or on the cell adhesion
molecules E-selectin, intercellular adhesion molecule-1 and
vascular cell adhesion molecule-1 (38). In that study, as in
the present study, patients continued on medical therapy. It
is possible that conventional treatment has a beneficial effect
on endothelial function (which in the present study was only
modestly impaired), masking effects of oral L-arginine. For
L-arginine to be of therapeutic value, however, effects over
and above conventional therapy would be necessary.
An alternative possibility is that improvement with di-
etary L-arginine may depend upon the predominant mech-
anism underlying the endothelial dysfunction. Young pa-
tients with marked hypercholesterolemia or patients with
nonobstructive CAD, for example, may benefit from oral
L-arginine to a greater extent than older patients with
symptomatic coronary atherosclerosis. It is possible that, in
younger patients with uncomplicated hypercholesterolemia,
the arginine/ADMA ratio is a more important determinant
of endothelial function, as in the hypercholesterolemic
rabbit.
Conclusion. In men with stable angina and mild hyper-
cholesterolemia, elevating the L-arginine/ADMA ratio
with oral L-arginine does not improve endothelium-
dependent vasodilation. A decreased L-arginine/ADMA
ratio may not be the predominant mechanism underlying
endothelial dysfunction in this group of patients. Further-
more, L-arginine does not possess significant anti-oxidant
or anti-anginal activities in such patients.
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